Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure

Robert Elsby, Paul Martin, Dominic Surry, Pradeep Sharma and Katherine Fenner
Drug Metabolism and Disposition March 2016, 44 (3) 398-408; DOI: https://doi.org/10.1124/dmd.115.066795
Robert Elsby
DMPK, Drug Safety and Metabolism (R.E., D.S.), and Quantitative Clinical Pharmacology, (P.M.), AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; and DMPK, Drug Safety and Metabolism, AstraZeneca R&D Darwin, Cambridge, Cambridgeshire, United Kingdom (P.S., K.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Martin
DMPK, Drug Safety and Metabolism (R.E., D.S.), and Quantitative Clinical Pharmacology, (P.M.), AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; and DMPK, Drug Safety and Metabolism, AstraZeneca R&D Darwin, Cambridge, Cambridgeshire, United Kingdom (P.S., K.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominic Surry
DMPK, Drug Safety and Metabolism (R.E., D.S.), and Quantitative Clinical Pharmacology, (P.M.), AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; and DMPK, Drug Safety and Metabolism, AstraZeneca R&D Darwin, Cambridge, Cambridgeshire, United Kingdom (P.S., K.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pradeep Sharma
DMPK, Drug Safety and Metabolism (R.E., D.S.), and Quantitative Clinical Pharmacology, (P.M.), AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; and DMPK, Drug Safety and Metabolism, AstraZeneca R&D Darwin, Cambridge, Cambridgeshire, United Kingdom (P.S., K.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Fenner
DMPK, Drug Safety and Metabolism (R.E., D.S.), and Quantitative Clinical Pharmacology, (P.M.), AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; and DMPK, Drug Safety and Metabolism, AstraZeneca R&D Darwin, Cambridge, Cambridgeshire, United Kingdom (P.S., K.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 44 no. 3 398-408
DOI 
https://doi.org/10.1124/dmd.115.066795
PubMed 
26700956

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received August 13, 2015
  • Accepted December 18, 2015
  • Published online February 9, 2016.

Article Versions

  • Earlier version (December 23, 2015 - 07:03).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Robert Elsby1,
  2. Paul Martin,
  3. Dominic Surry2,
  4. Pradeep Sharma, and
  5. Katherine Fenner
  1. DMPK, Drug Safety and Metabolism (R.E., D.S.), and Quantitative Clinical Pharmacology, (P.M.), AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; and DMPK, Drug Safety and Metabolism, AstraZeneca R&D Darwin, Cambridge, Cambridgeshire, United Kingdom (P.S., K.F.)
  1. Address correspondence to:
    Katherine Fenner, DMPK, Drug Safety and Metabolism, AstraZeneca R&D Darwin, Cambridge, Cambridgeshire, CB4 0WG, United Kingdom. E-mail: Katherine.Fenner{at}astrazeneca.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: December 2015 to May 2022

AbstractFullPdf
Dec 2015163086
Jan 20163980175
Feb 201670831102
Mar 20162684156
Apr 20161813444
May 20161062335
Jun 2016753234
Jul 2016791522
Aug 2016482221
Sep 2016491323
Oct 20161214042
Nov 2016583332
Dec 2016313523
Jan 2017882219
Feb 2017284734
Mar 201756233
Apr 201757140
May 201785168
Jun 201766152
Jul 201723823
Aug 2017106174
Sep 2017966157
Oct 2017205676
Nov 2017134157
Dec 201784116
Jan 2018105938
Feb 2018104833
Mar 201854424
Apr 201865344
May 201857428
Jun 201865047
Jul 201845937
Aug 201844734
Sep 201884734
Oct 201866647
Nov 2018610045
Dec 201848659
Jan 20191312258
Feb 201957834
Mar 201955535
Apr 201975541
May 2019113737
Jun 201983936
Jul 2019105346
Aug 2019105643
Sep 201955240
Oct 201943828
Nov 201984533
Dec 201974830
Jan 2020134777
Feb 2020133871
Mar 2020125673
Apr 2020164759
May 2020412575
Jun 202068353
Jul 202067642
Aug 2020114463
Sep 2020106053
Oct 202087584
Nov 2020157274
Dec 202097052
Jan 2021116954
Feb 2021146457
Mar 2021174338
Apr 2021176655
May 202176057
Jun 2021135726
Jul 202193733
Aug 202155750
Sep 202175844
Oct 2021106473
Nov 2021106364
Dec 2021115146
Jan 202295343
Feb 20221092528
Mar 2022812412
Apr 2022801117
May 20224193

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 44 (3)
Drug Metabolism and Disposition
Vol. 44, Issue 3
1 Mar 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Inhibition of Intestinal BCRP Increases Rosuvastatin Exposure

Robert Elsby, Paul Martin, Dominic Surry, Pradeep Sharma and Katherine Fenner
Drug Metabolism and Disposition March 1, 2016, 44 (3) 398-408; DOI: https://doi.org/10.1124/dmd.115.066795

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Inhibition of Intestinal BCRP Increases Rosuvastatin Exposure

Robert Elsby, Paul Martin, Dominic Surry, Pradeep Sharma and Katherine Fenner
Drug Metabolism and Disposition March 1, 2016, 44 (3) 398-408; DOI: https://doi.org/10.1124/dmd.115.066795
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Role of Human MSRA on Sulindac Activation
  • Determination of Acyl-, O-, and N-Glucuronide
  • TMDD Affects PK of IL-10 Fc-fusion Proteins
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics